Ideaya Begins Combination Trial for MTAP-Deleted Tumors; Shares Rise
Ideaya Biosciences reported the initiation of a phase 1 clinical trial testing IDE892, an MTA-cooperative PRMT5 inhibitor, alongside IDE397, an MAT2A inhibitor, in patients with MTAP-deleted solid tumors. The combination trial has enrolled its first patient and targets non-small cell lung cancer and pancreatic cancer. The company noted supportive p…